Identification of carbonic anhydrase 9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells

FEBS Journal

Volumn 277, Issue 21, 2010, Pages 4506-4518

  Zheng, Guopei ^a   Zhou, Min ^a   Ou, Xinrong ^b   Peng, Bo ^a   Yu, Yanhui ^a   Kong, Fangren ^a   Ouyang, Yongmei ^a   He, Zhimin ^a  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CA9; cDNA microarray; Drug resistance; Pingyangmycin; Tongue cancer

Indexed keywords

BLEOMYCIN A5; BREAST CANCER RESISTANCE PROTEIN; CARBONATE DEHYDRATASE IX; CISPLATIN; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GENE PRODUCT; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PIRARUBICIN; TONGUE CANCER DRUG RESISTANCE ASSOCIATED PROTEIN; UNCLASSIFIED DRUG; ACETAZOLAMIDE; ANTINEOPLASTIC ANTIBIOTIC; ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; DRUG DERIVATIVE; TUMOR ANTIGEN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DNA MICROARRAY; DNA SEQUENCE; DOWN REGULATION; DRUG SENSITIVITY; EXPRESSED SEQUENCE TAG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; NUCLEOTIDE SEQUENCE; PH; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TONGUE CANCER; UNINDEXED SEQUENCE; UPREGULATION; WESTERN BLOTTING; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TONGUE TUMOR; TUMOR CELL LINE;

ACETAZOLAMIDE; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BLEOMYCIN; BLOTTING, WESTERN; CARBONIC ANHYDRASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TONGUE NEOPLASMS;

EID: 79952110177     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07836.x     Document Type: Article

References (43)

1. Landis SH, Murray T, Bolden S & Wingo PA (1999) Cancer statistics 1999. CA Cancer J Clin 49, 8-31.
2. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG & Coman WB (2006) Head and neck cancer: past, present and future. Exp Rev Anticancer Ther 6, 111-118.
3. Moore SR, Johnson NW, Pierce AM & Wilson DF (2000) The epidemiology of tongue carcinoma: a review of global incidence. Oral Dis 6, 75-84. (Pubitemid 30159034)
4. Pignon JP, Bourhis J, Domenge C & Designé L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Mete-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355, 949-955.
5. Chen XQ, Jian XC & Guo F (2002) Retrospective study on the patients with tongue squamous cell carcinoma to pinyangmycin preoperative chemotherapy. Lin Chuang Kou Qiang Yi Xue Za Zhi 18, 126-127.
6. Zhang Y (2003) Therapeutic efficacy of adjuvant pinyangmycin for preoperative chemotherapy in treatment of 77 patients with tongue cancer. Tian Jin Yi Ke Da Xue Xue Bao 9, 511-513.
7. Leng WD, Wang DZ, Feng G & He J (2004) Expression and implication of Pgp, MRP, LRP, GST-π, Top-α in tongue squamous cell carcinoma. West China J Stomatol 1, 23-25.
8. Tai KW, Chang YC, Chou LSS & Chou MY (1998) Cytotoxicity effect of pingyangmycin on cultured KB cells. Oral Oncol 34, 219-223.
9. Li XT (1990) Anticancer spectrum of pingyangmycin in vitro. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 12, 182-186.
10. Zhong PQ, Zhi FX, Li R, Xue JL & Shu GY (1998) Long-term results of intratumorous bleomycin-A5 injection for head and neck lymphangioma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86, 139-144. (Pubitemid 128644701)
11. Dean M, Fojo T & Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284. (Pubitemid 40488633)
12. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R et al. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of human cancer xenografts to anticancer drugs. Cancer Res 62, 518-527. (Pubitemid 34106426)
13. Pastorekova S, Zatovicova M & Pastorek J (2008) Cancer associated carbonic anhydrases and their inhibition. Curr Pharm Des 14, 685-698. (Pubitemid 351736449)
14. Murakami Y, Kanda K, Tsuji M, Kanayama H & Kagawa S (1999) MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 83, 743-747. (Pubitemid 29224388)
15. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60, 7075-7083. (Pubitemid 32059187)
16. Robertson N, Potter C & Harris AL (2004) Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64, 6160-6165. (Pubitemid 39129417)
17. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC & Harris AL (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7, 3399-3403. (Pubitemid 33069972)
18. Pouyssegur J, Dayan F & Mazure NM (2006) Hypoxia signaling in cancer and approaches to enforce tumour regression. Nature 441, 437-443. (Pubitemid 44050138)
19. Brahimi-Horn MC, Chiche J & Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19, 223-229. (Pubitemid 46386401)
20. Roos A & Boron WF (1981) Intracelluar pH. Physiol Rev 61, 296-434.
21. Pouyssegur J, Sardet C, Franchi A, L'Allemain G & Paris S (1984) A specific mutation abolishing Na+/H+ antiport activity in hamster fibroblasts precludes growth at neutral and acidic pH. Proc Natl Acad Sci USA 81, 4833-4837. (Pubitemid 14066209)
22. Chambard JC & Pouyssegur J (1986) Intracellular pH controls growth factor-induced ribosomal protein S6 phosphorylation and protein synthesis in the G0-G1 transition of fibroblasts. Exp Cell Res 164, 282-294.
23. Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC & Pouysségur J (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69, 358-368.
24. Matsuyama S, Llopis J, Deveraux QL, Tsien RY & Reed JC (2000) Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol 2, 318-325.
25. Nagel WW & Vallee BL (1995) Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci USA 92, 579-583.
26. Jayasurya A, Bay BH, Yap WM & Tan NG (2000) Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br J Cancer 82, 1198-1203. (Pubitemid 30128879)
27. Theocharis SE, Margeli AP & Koutselinis A (2003) Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 18, 162-169. (Pubitemid 37254280)
28. Miyazaki H, Naitoh Y, Nakahashi Y, Yanagitani S, Kuno K, Ueno Y, Okajima A & Inoue K (1998) Induction of metallothionein isoforms in rat hepatoma cells by various anticancer drugs. J Biochem 124, 65-71. (Pubitemid 28379476)
29. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH & Lazo JS (1998) Over expression of metallothionein confers resistance to anticancer drugs. Science 241, 1813-1815.
30. Wang GW, Klein JB & Kang YJ (2001) Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther 298, 461-468. (Pubitemid 32673395)
31. Chun JH, Kim HK, Kim E, Kim IH, Kim JH, Chang HJ, Choi IJ, Lim HS, Kim IJ, Kang HC et al. (2004) Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res 64, 4703-4706. (Pubitemid 38924509)
32. Yang F, Zhou M, He Z, Liu X, Sun L, Sun Y & Chen Z (2007) High-yield expression in Escherichia coli of soluble human MT2A with native functions. Protein Expr Purif 53, 186-194. (Pubitemid 46283463)
33. Jin Y, Tipoe GL, Liong EC, Lau TY, Fung PC & Leung KM (2001) Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol 37, 225-233.
34. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P & Langenfeld J (2003) The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24, 1445-1454. (Pubitemid 37160834)
35. Langenfeld EM & Langenfeld J (2004) Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2, 141-149. (Pubitemid 39030304)
36. Reya T & Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434, 843-850. (Pubitemid 40558990)
37. Bafico A, Liu G, Yaniv A, Gazit A & Aaronson SA (2001) Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3, 683-686. (Pubitemid 32624426)
38. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C et al. (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signaling. Nature 417, 664-667. (Pubitemid 34614827)
39. Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N, Mikami I, Batra S & Jablons DM (2004) Dickkopf-1 antagonizes Wnt signalling independent of β-catenin in human mesothelioma. Biochem Biophys Res Commun 323, 1246-1250. (Pubitemid 39296559)
40. Mikheev AM, Mikheeva SA, Liu B, Cohen P & Zarbl H (2004) Functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. Carcinogenesis 25, 47-59. (Pubitemid 38128618)
41. Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J, Garc?́a JM, Muñoz A, Esteller M & González-Sancho JM (2006) Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 gene in human colorectal cancer. Oncogene 25, 4116-4121. (Pubitemid 44024874)
42. Vibhakar R, Foltz G, Yoon JG, Field L, Lee H, Ryu GY, Pierson J, Davidson B & Madan A (2007) Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neurooncology 9, 135-144. (Pubitemid 46580315)
43. Livak KJ & Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 25, 402-408. (Pubitemid 34164012)